



Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli,¹ Juan Carlos Hernández-Boluda,² Francesco Onida,³ Carmelo Gurnari,^{4,5} Kavita Raj,⁶ Tomasz Czerw,⁷ Michelle Kenyon,⁸ Marie Robin,⁹ Katja Sockel,¹⁰ Annalisa Ruggeri,¹¹ Isabel Sánchez-Ortega,¹² Daniel A. Arber,¹³ Luca Arcaini,^{1,14} Fernando Barroso Duarte,¹⁵ Giorgia Battipaglia,¹⁶ Yves Chalandon,^{17,18} Fabio Ciceri,¹¹ Nicholas C. P. Cross,¹⁹ Joanna Drozd-Sokolowska,²⁰ Vaneuza Funke,²¹ Nico Gagelmann,²² Naseema Gangat,²³ Jason Gotlib,²⁴ Paola Guglielmelli,²⁵ Claire Harrison,²⁶ Gabriela Hobbs,²⁷ Tania Jain,²⁸ Joseph D. Khoury,²⁹ Jean Jacques Kiladjian,⁸ Nicolaus Kröger,²² Luca Malcovati,^{1,14} Massimo Martino,³⁰ Ruben Mesa,³¹ Attilio Orazi,³² Eric Padron,³³ Francesca Palandri,³⁴ Francesco Passamonti,^{35,36} Mrinal M. Patnaik,²³ Naveen Pemmaraju,³⁷ Deepti H. Radia,²⁶ Andreas Reiter,³⁸ Domenico Russo,³⁹ Christof Scheid,⁴⁰ Ayalew Tefferi,²³ Alessandro M. Vannucchi,²⁵ Daniel H. Wiseman,⁴¹ Ibrahim Yakoub-Agha,⁴² and Donal P. McLornan⁴³

¹Unit of Bone Marrow Transplantation and Cellular Therapies, Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy; ²Hospital Clínico Universitario, Universidad de Valencia, Valencia, Spain; ³Practice Harmonisation and Guidelines Committee of the European Society for Blood and Marrow Transplantation, Hematology and Bone Marrow Transplantation Unit, Azienda Socio Sanitaria Territoriale Fatebenefratelli-Sacco, Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; ⁴Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; ⁵Department of Translational Hematology and Oncology Research, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH; ⁶Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom; ⁷Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland; ⁸Department of Haematology, King's College Hospital, London, United Kingdom; ⁹Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Paris, France; ¹⁰Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany; ¹¹Practice Harmonisation and Guidelines Committee of European Society for Blood and Marrow Transplantation and Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation, Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy; ¹²Practice Harmonisation and Guidelines Committee of European Society for Blood and Marrow Transplantation, Executive Office, Barcelona, Spain; ¹³Department of Pathology, University of Chicago, Chicago, IL; ¹⁴Department of Molecular Medicine, University of Pavia, Pavia, Italy; ¹⁵Hospital Universitario Walter Cantídio, Universidade Federal do Ceará, Fortaleza, Brazil; ¹⁶Department of Clinical Medicine and Surgery, Haematology Unit, Federico II University of Naples, Naples, Italy; ¹⁷Service d'Hématologie, Département d'Oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland; ¹⁸Faculty of Medicine, University of Geneva, Geneva, Switzerland; ¹⁹Wessex Genomics Laboratory Service, Salisbury NHS Foundation Trust, Salisbury, United Kingdom; ²⁰University Clinical Centre Medical University of Warsaw, Warsaw, Poland; ²¹Blood and Marrow Transplantation Program, Hospital de Clínicas, Federal University of Paraná, Curitiba, Paraná, Brazil; ²²Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ²³Division of Hematology, Mayo Clinic, Rochester, MN; ²⁴Stanford Cancer Institute, Stanford, CA; ²⁵Center Research and Innovation of Myeloproliferative Neoplasms, Dipartimento di Medicina Sperimentale e Clinic, University of Florence, Azienda Ospedaliero Universitaria Careggi, Florence, Italy; ²⁶Department of Haematology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom; ²⁷Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA; ²⁸Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; ²⁹Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, NE; ³⁰Hematology and Stem Cell Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli,” Reggio Calabria, Italy; ³¹Wake Forest University School of Medicine, Winston-Salem, NC; ³²Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX; ³³Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; ³⁴Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Bologna, Italy; ³⁵Dipartimento di Oncologia ed Onco-Ematologia, Università Degli Studi di Milano, Milan, Italy; ³⁶Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ³⁷Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; ³⁸Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany; ³⁹Department of Clinical and Experimental Science, University of Brescia, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy; ⁴⁰University of Cologne, Cologne, Germany; ⁴¹Division of Cancer Sciences, Epigenetics of Haematopoiesis Laboratory, The University of Manchester, Manchester, United Kingdom; ⁴²Practice Harmonisation and Guidelines Committee of the European Society for Blood and Marrow Transplantation Centre Hospitalier Universitaire de Lille, University Lille, INSERM U1286, Infinite, Lille, France; and ⁴³European Society for Blood and Marrow Transplantation Chronic Malignancies Working Party, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

“Nonclassical” myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. Unlike classical MPNs, there is no standardized management approach for these conditions, particularly concerning the indications for and management of allogeneic hematopoietic cell transplantation. To address

this gap, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines (PH&G) Committee and the Chronic Malignancies Working Party (CMWP) have collaborated to develop shared guidelines aimed at optimizing the selection and management of patients with these rare forms of neoplasms. A comprehensive review of the literature from the publication of the revised fourth

edition of the (2016) World Health Organization classification onward was conducted. A multidisciplinary group of experts in the field convened to produce this document, which was developed through multiple rounds of draft circulation. Key recommendations include the early identification of potential transplant candidates, particularly in cases of chronic neutrophilic leukemia, chronic eosinophilic leukemia (CEL)/CEL, not otherwise specified (CEL-NOS), myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions with *FGFR1*, *JAK2*, *ABL1*, and *FLT3*

rearrangements, MDS/MPN with neutrophilia/atypical chronic myeloid leukemia, and MDS/MPN, NOS. For patients with MPN, NOS/MPN unclassifiable, standard recommendations for myelofibrosis should be applied. Similarly, in MDS/MPN with thrombocytosis, transplantation is recommended on the basis of established MDS guidelines. Given the current lack of robust evidence, this document will serve as a valuable resource to guide future research activities, providing a framework for addressing critical unanswered questions and advancing the field.

Introduction

Myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) represent a heterogeneous and complex group of hematological malignancies. Recent refinements introduced by the World Health Organization (WHO) classification of tumors and International Consensus Classification (ICC) have enhanced our understanding and categorization of these conditions.^{1,2} These entities frequently display a broad spectrum of clinical manifestations and can present significant challenges to accurate diagnosis, prognostication, and treatment. Among “classical” MPNs, chronic myeloid leukemia (CML), essential thrombocythemia, polycythemia vera, and myelofibrosis (MF) are the most frequently recognized. Several recent publications have addressed the primary treatment goals and the role of transplant in these conditions.³⁻⁵ Similarly, chronic myelomonocytic leukemia (CMML) is the most common form of MDS/MPN, and contemporary management has been thoroughly discussed in the recent literature.⁶ By contrast, because of their relative rarity and hence limited cumulative evidence base, adult “nonclassical” forms of MPNs and MDS/MPNs remain an area with significant unmet need in terms of both diagnosis and clinical management. These uncommon disorders include chronic neutrophilic leukemia (CNL) (WHO/ICC), chronic eosinophilic leukemia (CEL) (WHO)/CEL, not otherwise specified (NOS) (ICC), myeloid/lymphoid neoplasms (MLNs) with eosinophilia and tyrosine kinase (TK) gene fusions (MLN-TK) (WHO/ICC), and MPN, NOS (WHO)/MPN-unclassifiable (U) (ICC) among the MPNs. In addition, MDS/MPN with neutrophilia (WHO)/atypical CML (aCML) (ICC), MDS/MPN with *SF3B1* mutation and thrombocytosis (WHO)/MDS/MPN with thrombocytosis and *SF3B1* mutation (ICC), MDS/MPN with ring sideroblasts and thrombocytosis, NOS (recognized only by ICC), and MDS/MPN, NOS (WHO/ICC) are included under the spectrum of MDS/MPN diseases.^{1,2}

The prognosis for patients with such nonclassical MPNs and MDS/MPNs varies widely based on the specific subtype, molecular landscape, and individual patient factors. Although some patients experience a relatively indolent disease course, others may display an aggressive disease course with significant rates of morbidity and a markedly reduced life expectancy. Thus, allogeneic hematopoietic stem cell transplantation (HCT) remains a viable option for eligible patients, despite inherent

risks in terms of both morbidities and nonrelapse mortality (NRM). The rarity, heterogeneity, and complexity characteristics to the management of these disorders underscore the need for standardized best practice recommendations, particularly in the context of HCT. These recommendations are key to address critical issues, such as ideal patient selection, pretransplant treatment strategies, optimal timing for HCT, and comprehensive transplant policies. Given these challenges, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines Committee has prioritized the development of best practice recommendations for the management of adult patients with nonclassical MPNs and MDS/MPNs undergoing HCT. These recommendations aim to provide a cohesive framework to improve patient outcomes and harmonize clinical practices across treatment centers internationally.

Methodology

This workshop was conducted according to the method published by the EBMT Practice Harmonization and Guidelines Committee.⁷ The Chronic Malignancies Working Party of the EBMT proposed the development of practice recommendations for nonclassical MPNs and MDS/MPNs. To comprehensively assess the scope of the issue, the EBMT registry was analyzed, collecting data on transplant procedures for each indication starting from 2016, following the release of the fourth edition of the WHO classification (Table 1). Despite the limited number of cases, transplant procedures have shown a consistent upward trend in recent years, suggesting a growing awareness of such diseases.

A list of global experts and key opinion leaders in the field, including hematologists, hematopathologists, molecular biology specialists, and transplant physicians, was compiled on the basis of their professional experience, prior research, and relevant scientific contributions. Key clinical questions and areas of unmet clinical needs were identified to guide consensus development, organized into 3 distinct sections (supplemental Material, available on the *Blood* website).

During the initial meeting in June 2024, experts formed specific subgroups to focus on individual topics. A comprehensive literature search of PubMed/MedLine until September 2024 was conducted for each key question, identifying indexed

Table 1. Number of transplant procedures for nonclassical MPNs and MDS/MPNs performed in Europe from 2016 to 2023

Diagnosis	Year of HCT	2016 Frequency	2017 Frequency	2018 Frequency	2019 Frequency	2020 Frequency	2021 Frequency	2022 Frequency	2023 Frequency
MPN	CNL (WHO/ICC)	4	7	11	9	13	8	10	10
	CEL (WHO)/CEL, NOS (ICC)	1	1	4	—	2	1	3	4
	MLN-TK with <i>ABL1</i> rearrangement	—	—	—	—	—	—	—	—
	MLN-TK with <i>FGFR1</i> rearrangement	2	3	5	1	3	2	—	1
	MLN-TK with <i>FLT3</i> rearrangement	—	—	—	—	—	—	—	—
	MLN-TK with <i>JAK2</i> rearrangements	—	—	—	—	—	1	1	4
	MLN-TK with <i>PDGFRA/B</i> rearrangement	—	—	—	—	—	—	—	1
	MPN, NOS (WHO)/ MPN-U (ICC)	37	35	37	46	42	46	42	80
	Total nonclassical MPN	44	46	57	56	60	58	56	100
MDS/MPN	MDS/MPN with neutrophilia (WHO)/aCML (ICC)	37	32	40	44	36	40	38	40
	MDS/MPN with ring sideroblasts and thrombocytosis, NOS (ICC only)	—	—	—	—	—	1	2	7
	MDS/MPN with <i>SF3B1</i> mutation and thrombocytosis (WHO)/MDS/MPN with thrombocytosis and <i>SF3B1</i> mutation (ICC)	—	—	—	—	—	—	—	—
	MDS/MPN, NOS (WHO/ICC)	59	84	98	91	107	99	112	86
	Total nonclassical MDS/MPN	96	116	138	135	143	140	152	133

articles. In accordance with the EBMT practice recommendation method, and because of the lack of prospective studies, the evidence was derived from retrospective studies, reviews, and expert opinions, without formal evidence grading.

A task force was established to draft panel positions addressing the identified key questions. These drafts underwent multiple iterations within respective subgroups. A hybrid face-to-face and virtual meeting with EBMT members was held on 30 September 2024 and 1 October 2024, in Lille, France, to finalize the recommendations.

The primary goal of the meeting was to develop a comprehensive draft consensus manuscript, which was subsequently reviewed by all authors to finalize these agreed-upon best practice recommendations with a focus on the identification and pretransplant and posttransplant management of patients with nonclassical MPN and MDS/MPN, where relevant literature was available. All recommendations were considered valid if an agreement of >80% was reached. Table 2 presents a list of the key publications in the field of transplantation for these entities.

Current state-of-the-art approaches

Molecular landscape of nonclassical MPNs and MDS/MPNs

The application of next-generation sequencing (NGS) technology to large cohorts of patients with nonclassical MPNs and MDS/MPNs has unveiled molecular features characterizing, but not defining, the individual nosological disease types, now recognized in the most recent diagnostic classifications (see below [Comparison of WHO/ICC classifications](#)).^{1,2} Particularly, studies focusing on the molecular architecture of these disorders identified specific comutational patterns underpinning the multistep pathogenesis linked to the clinical heterogeneity of these nonclassical MPNs and MDS/MPNs.

Nonclassical MPNs are frequently diagnosed on the basis of prominent clinical features (eg, eosinophilia, splenomegaly, and leukocytosis), and absence of criteria fulfilling the diagnosis of classical MPNs. Some, but not all, are characterized by specific molecular patterns:

1. CNL is strongly, but not exclusively, associated with pathogenetic *CSF3R* mutations.
2. CEL is a diagnosis of exclusion with no indicative molecular features.
3. MLN-TK have disease-defining gene alterations: *PDGFRA*, *PDGFRB*, *FGFR1*, *JAK2*, *FLT3*, and *ETV6::ABL1* and other tyrosine-kinase alterations.
4. Cases with MPN, NOS/U typically have *JAK2*, *CALR*, or *MPL* mutations but do not meet the hematological and histopathologic criteria for classical MPN.

Within the MDS/MPN entities, conventional cytogenetics can identify clonality/aberrations in 15% to 35% of cases, most typically in MDS/MPN with neutrophilia/aCML,¹⁷ whereas NGS panels show recurrent myeloid gene mutations in ~90% of cases.¹⁸ Mutations in epigenetic regulators (*ASXL1*, *TET2*, and *DNMT3A*), splicing (*SF3B1*, *SRSF2*, and *U2AF1*), the JAK-STAT pathway (*JAK2*, *CALR*, and *MPL*), and the rat sarcoma virus

(RAS) pathway (*NRAS*, *KRAS*, and *CBL*) genes are the most recurrent alterations.¹⁷ In general, the combination and order of acquisition of such lesions dictate the clinicopathologic presentation. The current classification is not strictly segregated according to molecular lesions, such that mutations may occur promiscuously across these entities. However, several studies have highlighted that patients with MDS/MPN could be broadly characterized by their genomic make-up:^{17,19,20}

1. MDS/MPN with neutrophilia/aCML frequently carry *SETBP1* and/or *ASXL1* mutations.
2. "MDS/MPN with ring sideroblasts and thrombocytosis" cases are dominated by *SF3B1* and often *JAK2* mutations or, at a low frequency, *CALR* or *MPL* mutations.
3. Especially in MDS/MPN, NOS, molecular mutations can be useful for further disease stratification. Genotypically patients with "CMML-like" MDS/MPN, NOS show enrichment for *TET2*, as well as *SRSF2*, *ASXL1*, *RUNX1*, and RAS pathway alterations.
4. Phenotypically, patients with "MDS/MPN with neutrophilia-like" MDS/MPN, NOS show enrichment for *ASXL1*, *SETBP1*, *ETNK1*, *RUNX1*, *TET2*, and RAS pathway gene mutations.

The current WHO/ICC classifications incorporate only *SF3B1* as a disease-defining lesion in the MDS/MPN and thrombocytosis category.

Apart from these recurrent genomic profiles, some less frequent mutations may identify cases with specific clinical trajectories and outcomes (eg, *TP53*, *CBL*).²¹ Genomic information may help to establish an accurate diagnosis, enhance prognostication, and even support reclassification of ambiguous cases into currently defined disease entities, supplementing pathomorphologic and clinical criteria.²²

Comparison of WHO/ICC classifications

The fifth edition of the WHO classification² and the ICC of myeloid and lymphoid neoplasms¹ are built on the revised fourth edition of the (2016) WHO classification.²³ For entities included in this article, the definitions and diagnostic criteria in the WHO fifth edition and ICC are similar, with some key differences as summarized in Table 3.

Regarding MPN classification, the definition of CNL remained unchanged in the WHO fifth edition, whereas the ICC reduced the threshold of required neutrophilia ($>13 \times 10^9/L$) in the presence of a *CSF3R* mutation. The ICC defines both accelerated and blast phases. These definitions may enable therapeutic interventions and interpretations of outcomes in future trials. CEL continues to be recognized in the WHO fifth edition and ICC as an MPN characterized by persistent eosinophilia, clonality, and abnormal/dysplastic bone marrow morphology that does not fulfil the diagnostic criteria of MLN with eosinophilia and TK fusions (MLN-TK) or other defined myeloid neoplasms that may present with eosinophilia. Although both classifications regard CEL as a diagnosis of exclusion in patients with sustained eosinophilia, they differ in minor aspects.

In the category of MDS/MPNs, the WHO fifth edition renamed aCML as MDS/MPN with neutrophilia but kept diagnostic parameters the same. The ICC maintained the name of aCML,

Table 2. Main publications reporting on transplant cohorts of patients with nonclassical MPN and MDS/MPN

Author (year)	MDS/MPN type	Patient No.	Tranplant period	Age, median (range), y	Donor	Conditioning	Stem cell source	NRM/relapse	Survival outcome
Dholaria (2022) ⁸	CNL	29	2000-2018	58 (33-72)	MRD 41% UD 56% MMRD 3%	MAC 48%	PB 93%	NRM 13.8% at 4y CIR 34.5% at 4y	OS 55.2% at 1 y
McLornan (2022) ⁹	CEL/CEL, NOS	30	2000-2018	46 (IQR, 40-55)	MRD 30% UD 67% MMRD 3%	MAC 61%	PB 67%	NRM 45% at 3y CIR 20% at 3y	OS 34% at 3 y
McLornan (2020) ¹⁰	MPN, NOS/MPN-U	70	2000-2015	NA (22-70)	MRD 39% UD 61%	MAC 44%	PB 91%	NRM 34% at 5y (MAC) CIR 27% at 5y (MAC)	OS 41% at 5 y (MAC)
Metzgeroth (2023) ¹¹	MLN-TK	25	2003-2022	NA	NA	NA	NA	NR	10/12 alive at 3 y (chronic phase) 7/13 alive at 4.7 y (blast phase)
Hernández-Boluda (2022) ¹²	MLN-TK with <i>FGFR1</i> rearrangement	22	1997-2018	51 (22-67)	MRD 23% UD 68% MMRD9%	MAC 55%	PB 86%	NRM 14% at 5y CIR 23% at 5y	OS 74% at 5 y
Tang (2021) ¹³	MLN-TK with <i>FLT3</i> rearrangement	6	2005-2020	34 (2-43)	NA	NA	NA	NA	4/6 alive in CR at a median follow-up of 41 mo
Onida (2017) ¹⁴	MDS/MPN with neutrophilia/aCML	42	1997-2006	46 (25-67)	MRD 64% UD 36%	MAC 76%	PB 67%	NRM 24% at 5y CIR 40% at 5y	OS 51% at 5 y
Itonaga (2018) ¹⁵	MDS/MPN with neutrophilia/aCML	14	2003-2014	45 (10-66)	MRD 36% UD 64%	MAC 86%	PB 14% BM 72% CB 14%	NRM 2 relapse/progression 4	8/14 alive at last follow-up
Kurosawa (2020) ¹⁶	MDS/MPN, NOS	86	2001-2017	57 (16-71)	MRD 28% UD 72%	MAC 62%	BM/PB 80% CB 20%	NRM 26% at 3y CIR 24% at 3y	OS 49% at 3 y

CB, cord blood; CIR, cumulative incidence of relapse; IQR, interquartile range; MAC, myeloablative conditioning; MMRD, mismatched related donor; MRD, measurable residual disease; NA, not available; PB, peripheral blood; UD, unrelated donor.

Table 3. Differences and similarities among the WHO (fifth edition) and ICC classifications

WHO revised fourth edition	WHO fifth edition	ICC	Differences or similarities
CNL	CNL Unchanged from 2016	CNL Similar to WHO revised fourth edition except: Lowering of threshold PB WBC $>13 \times 10^9/L$ if accompanied by <i>CSF3R</i> mutation Defines Accelerated phase as circulating or BM blasts 10%-19% with progressive splenomegaly or worsening thrombocytopenia Blast phase as circulating or BM blasts $\geq 20\%$	In the presence of <i>CSF3R</i> mutation—lowering of the PB WBC threshold to $>13 \times 10^9/L$ for diagnosis in ICC Definition of accelerated and blast phase added in ICC
CEL, NOS	CEL	CEL, NOS	Both exclude the growing number of tyrosine kinase gene fusions now categorized separately. WHO fifth edition drops the not otherwise specified (NOS) descriptor
Myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions	Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions	Both add expanded categories involving <i>JAK2</i> and <i>FLT3</i> rearrangements and add <i>ETV6::ABL1</i> fusion
MPN, U	MPN, NOS	MPN-U	Remains unchanged, with only minor terminology adjustments in the WHO fifth edition
Atypical CML, <i>BCR-ABL1</i> negative	MDS/MPN with neutrophilia Same as revised fourth edition but name changed	Atypical CML Essentially unchanged from revised fourth edition except to delete reference to the lack of <i>BCR::ABL1</i> gene fusion in the name	Significant terminology changes in WHO fifth edition
MDS/MPN with ring sideroblasts and thrombocytosis	MDS/MPN with <i>SF3B1</i> mutation and thrombocytosis	MDS/MPN with thrombocytosis and <i>SF3B1</i> mutation MDS/MPN with ring sideroblasts and thrombocytosis, NOS	The ICC distinguishes forms carrying the <i>SF3B1</i> mutation from those without
MDS/MPN, U	MDS/MPN, NOS	MDS/MPN, NOS	Remains unchanged, with only minor terminology adjustments in the WHO fifth edition

BM, bone marrow; PB, peripheral blood; WBC, white blood cell.

adding mutational status (*SETBP1* and/or *ASXL1*) as supportive of the diagnosis. Both classifications split MDS/MPN with ring sideroblasts and thrombocytosis into *SF3B1* mutated and unmutated. The ICC explicitly defined MDS/MPN with *SF3B1* and thrombocytosis to exclude therapy-related and other cytogenetic and genetic anomalies. The WHO fifth edition additionally recognizes that any MDS/MPN entity may arise after exposure to cytotoxic therapy. Both the WHO fifth edition and the ICC have renamed MDS/MPN, U, as MDS/MPN, NOS.

Disease-specific HCT indications

CNL (WHO/ICC)

CNL is a rare disorder presenting with leukocytosis and frequently splenomegaly. It has a variable clinical course but is ultimately associated with a poor prognosis, with a median survival of <2 years. Disease progression remains the primary cause of death.^{24,25} Conventional treatment strategies are highly variable, ranging from cytoreduction with hydroxycarbamide and interferon to use of targeted kinase inhibitors, such as ruxotinib or dasatinib, albeit responses are commonly short lived.²⁶ “Acute myeloid leukemia (AML)–style” induction

approaches may be considered in accelerated/blast-phase disease as a potential bridge to HCT in eligible patients, but the regimen of choice remains undetermined.²⁷

Features of progression include debilitating splenomegaly, treatment refractoriness and progressive neutrophilia, acquisition of transfusion dependency, and increasing genomic complexity.^{24,28} The presence/acquisition of pathogenetic mutations in *ASXL1*, *CBL*, *CEBPA*, *EZH2*, *NRAS*, *TET2*, and/or *U2AF1* are associated with poor overall prognosis.^{24,28}

Given the poor prognosis associated with conventional therapy, all patients with CNL should be assessed early after diagnosis for potential transplant eligibility. However, data addressing the HCT outcomes in this disease group are limited. The largest cohort published to date was a retrospective evaluation of 29 patients who underwent transplantation between 2000 and 2018 performed on behalf of the Center for International Blood and Marrow Transplant Research and the EBMT.⁸ Blast phase patients were excluded. Stem cell source was predominantly peripheral blood, with myeloablative conditioning (MAC) accounting for $\approx 50\%$, whereas nonmyeloablative/reduced

Table 4. Panel recommendations for CNL

Disease	Panel recommendations
CNL (WHO/ICC)	All patients with CNL should be assessed early following diagnosis for potential transplant eligibility and donor search Treatment aimed at optimizing disease control (control of leukocytosis, reduction in splenomegaly, where relevant) is recommended as a “bridge” before transplant, balancing the risks and benefits Given limited data, no recommendations can be made on optimal transplant conditioning regimens and posttransplant disease monitoring and maintenance. However, consideration needs to be given to considerable relapse rates and approaches tailored accordingly.

intensity conditioning (RIC) was used in the other 50%. Overall survival after transplantation exceeded 50% at 4 years, with limited NRM but relapse rate of 35% at 4 years (Table 2), underscoring the importance of rigorous posttransplant monitoring to detect early signs of disease recurrence. No specific studies are available on the use of pretransplant treatments as a bridge to HCT. However, given the limited disease modulation, pretransplant cytoreductive or tyrosine kinase inhibitor (TKI) therapy should be considered to enhance disease control (reduce white blood cell count; improve splenomegaly) and optimize the patient’s physical condition in preparation for HCT, balancing the risks and benefits while considering the potential use of such treatments (eg, infectious risk, disease progression).²⁴ Development of dynamic posttransplant measurable residual disease (MRD) analyses when a molecular marker is detected (eg, *CSF3R*) needs to be further investigated in this setting but is encouraged by the panel to collate such data where possible.²⁹ The use of maintenance therapy after transplant with agents such as ruxolitinib or dasatinib remains investigational. Panel recommendations for CNL are summarized in Table 4.

CEL (WHO)/CEL, NOS (ICC)

CEL (WHO)/CEL, NOS (ICC) is a rare, debilitating, and aggressive MPN with an augmented risk of organ failure (especially cardiac failure) because of eosinophilic infiltration and high rates of transformation to acute leukemia. Median survival is poor, often estimated at <2 years from time of diagnosis.^{30,31}

Therapeutic options range from supportive care approaches, including corticosteroids or hydroxycarbamide/interferon, to “AML-like” induction therapy and HCT; most cases frequently display limited response to therapy.^{30,31}

Data on the outcomes of HCT in CEL are limited to a single report by the EBMT on 30 patients who underwent transplant between 2000 and 2018.⁹ Median age was 46 years (interquartile range, 39-59 years), with a male predominance.

Stem cell source was peripheral blood derived in 67%, MAC used in 61%, unrelated donor (URD) used in 67%, and in vivo T-cell depletion in 52% of cases. The 1- and 3-year overall survival (OS) estimates were 46% and 34%, respectively; however, for patients with matched sibling donor, OS was 65% at 3 years. Transplant failure was attributable to high rates of NRM (38% at 1 year), particularly following use of a URD. This analysis was conducted before the widespread use of posttransplant cyclophosphamide, which suggests that outcomes for unrelated donor transplants may have improved in recent years.

Panel recommendations for CEL (WHO)/CEL, NOS (ICC) are summarized in Table 5.

Myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions (WHO/ICC)

According to both the ICC and WHO 2022 classifications, several MLNs associated with rearrangements of *PDGFRA*, *PDGFRB*, *FGFR1*, *JAK2*, *ABL1*, or *FLT3* tyrosine kinase genes (MLN-TK) fall within this categorization. These are rare malignancies with a frequently aggressive clinical course that can present as an MPN with a high tendency to blast phase transformation, or directly as AML, T or B lymphoblastic leukemia/lymphoma or mixed phenotype acute leukemia, with or without a concomitant MPN component. Cardiac eosinophilic infiltration is particularly prominent in patients with MLN-TK-*PDGFRA*.^{32,33} Recently, comprehensive response criteria have been proposed to address the heterogeneous clinical presentation of MLN-TK.³⁴

Treatment with TKI, primarily imatinib, is effective in most patients with MLN harboring *PDGFRA*³⁵ or *PDGFRB*³⁶ fusion genes, even in the blast phase.³⁷ This treatment can induce durable complete molecular remissions akin to those achieved in CML.³⁸ In the German registry, only 16 of 104 (15%) patients with *PDGFRA/B* fusion genes had died after a median follow-up of 9.2 years.¹¹ Acquired resistance to imatinib due to mutations has been reported in a few patients with primarily blast phase

Table 5. Panel recommendations for CEL (WHO)/CEL, NOS (ICC)

Disease	Panel recommendations
CEL (WHO)/CEL, NOS (ICC)	Given the poor prognosis of CEL/CEL, NOS and the risk of organ dysfunction, all patients should be considered for HCT at diagnosis with a prompt donor search Careful assessment of cardiac and pulmonary function is advised for transplant eligibility and then for tailoring transplant platform Given the lack of disease-modifying agents, no recommendation can be made on pretreatment strategies Transplant should not be delayed once a suitable donor is found

Table 6. Panel recommendations for MLN-TK (WHO/ICC)

Disease	Panel recommendations
MLN-TK (WHO/ICC)	In patients with <i>PDGFRA/B</i>-rearranged MLN, both in chronic and blast phases, HCT is only considered after failure of TKI treatment. However, in young patients (<60 y) presenting with blast-phase disease, HCT could be considered on achieving a response. Careful assessment of cardiac and pulmonary function is advised for transplant eligibility and then for tailoring transplant platform HCT, after bridging with an alternative TKI with or without chemotherapy, seems to be the preferred option for the rare cases of MLN-<i>PDGFRA/B</i> with secondary resistance to imatinib HCT with donor search should be considered early after diagnosis for most eligible patients with <i>FGFR1</i>-, <i>JAK2</i>-, <i>ABL1</i>-, and <i>FLT3</i>-rearranged MLN, given the low predictability and uncertain durability of responses to TKIs TKI treatment directed to the specific molecular abnormality is recommended to decrease disease burden pre-HCT A thorough evaluation of cardiac and pulmonary function is essential, given the possible organ impairment associated with prior/ongoing eosinophilic infiltration The HCT strategy should be tailored to the predominant clinical features of the disease (ie, AML, ALL, or MPN) Monitoring of the underlying molecular abnormality using sensitive techniques is advised to inform treatment strategies to prevent overt disease relapse The role of TKI maintenance after HCT warrants investigation

disease,^{39,40} although some of them may respond to alternative TKI (eg, ponatinib for T674I mutations or avapritinib for D842V mutations).^{41,42}

In contrast, patients with *FGFR1*, *JAK2*, *ABL1*, or *FLT3* fusion genes have less favorable responses to TKIs, often ultimately progressing to blast phase, with a median survival of ≈5 years in the German registry.^{11,43} However, exceptions may include patients with chronic phase MLN-*FGFR1* or MLN-*ETV6::ABL1*, who can achieve molecular responses to pemigatinib⁴⁴ or nilotinib/dasatinib,⁴³ respectively.

Nevertheless, the durability of these responses remains uncertain, and HCT constitutes the only treatment with demonstrated long-term disease control in these conditions. A recent retrospective study by the EBMT, including 22 patients with MLN-*FGFR1* undergoing HCT, reported rates of 5-year OS, progression-free survival, NRM, and relapse incidence of 74%, 63%, 14%, and 23%, respectively, underscoring the curative potential of HCT in this aggressive disease.¹² Among 12 patients with MLN-*FLT3* from several US institutions, 6 underwent HCT, with 4 still alive at the last follow-up.¹³

On the basis of these data, early referral to HCT is recommended for most eligible patients with *FGFR1*, *JAK2*, *ABL1*, or *FLT3* fusion genes in chronic phase, because TKI treatment typically does not yield durable remissions, and the disease can rapidly progress to blast phase.^{33,44} Patients with MLN-*FGFR1* or MLN-*ETV6::ABL1* who achieve deep responses to TKIs (pemigatinib for *FGFR1* or nilotinib/dasatinib for *ABL1*) might delay transplant if predicted to be at high risk for NRM, with close monitoring of their TKI response and reconsideration if warning signals arise. In general, bridging therapy with a specific TKI with or without chemotherapy should be considered. Patients ineligible for HCT should be considered for clinical trials. Finally, the role of TKI maintenance after HCT deserves investigation in a standardized manner. Table 6 summarizes the panel recommendations for MLN-TK.

MPN, NOS (WHO)/MPN-U (ICC)

MPN, NOS/MPN-U encompasses a heterogeneous group of MPNs that fail to meet stringent diagnostic criteria of other

MPN entities within the WHO or ICC classification systems.^{1,2} True incidence remains unknown, but it is estimated to represent 5% of all MPNs if strict diagnostic criteria are applied.⁴⁵ Dynamic reassessment is warranted, as over time the characteristics may meet the diagnostic criteria of other MPN entities. Clinical phenotype is markedly heterogeneous—ranging from those with an indolent disease course to those with aggressive disease associated with significant splenomegaly and symptom burden and inherent risk of leukemic transformation.^{46,47} A large series from a United Kingdom tertiary center, with median follow-up of >7 years, suggested thrombotic complications in ≈20% of patients and transformation rates of ≈9%, highlighting the need for close vigilance.⁴⁶ Median event-free survival was 11 years. Recently, a retrospective study by Crane et al, comprising 94 patients, reported a median OS of 54 months.⁴⁸ Interestingly, the Dynamic International Prognostic Scoring System-plus model and high-risk molecular profile retained prognostic relevance, suggesting that MF-derived prognostic scores may be used to inform prognosis also in this context.

McLoman et al reported an EBMT registry-based evaluation of outcomes following HCT in 70 patients with a verified diagnosis of MPN, NOS/MPN-U, representing the largest transplant cohort reported to date.¹⁰ Regarding conditioning intensity, 31 patients underwent MAC and 39 patients underwent RIC. There was a nonsignificant trend toward delayed engraftment with RIC protocols. The 1- and 5-year OS estimates were 77% and 42% (MAC) and 59% and 41% (RIC), respectively. NRM rates at 1 and 3 years were considerable at 19% and 29% for MAC and 28% and 28% for RIC, respectively. Cumulative incidences of relapse at 1 and 3 years were 10% and 23% (MAC) and 28% and 36% (RIC), respectively. Risk of relapse tended to be higher in those patients with MPN-NOS who had an abnormal karyotype at time of HCT. Regarding donor type, univariate analysis suggested worse OS and NRM rates with use of a URD compared with matched sibling donor.

Given the rarity of the disease group, any recommendations for HCT are solely translated from experience with other MPNs, predominantly MF. Pragmatically, as it has been previously suggested, consideration to HCT in transplant-eligible individuals with MPN, NOS/MPN-U who have a suitable donor may

Table 7. Panel recommendations for MPN, NOS (WHO)/MPN, U (ICC)

Disease	Panel recommendations
MPN, NOS (WHO)/MPN-U (ICC)	Given disease heterogeneity, therapeutic approaches to MPN, NOS should be discussed in centers with expertise in MPN management In patients with transplant-eligible MPN, NOS, HCT can be considered for those patients at higher risk according to standard MF-derived prognostic systems It is recommended that standard guidelines for MF pertaining to transplant are applied

include those ascertained as having higher risk disease (ie, those with increasing peripheral blood/marrow blasts), acquisition of cytogenetic or mutational profiles predicted to be associated with a worse prognosis (transcribed from MF data as no sufficient evidence in MPN, NOS/MPN-U), progressive debilitating splenomegaly despite optimized medical therapy, or those who become transfusion dependent.^{3,4,46,47,49,50} From a practical stance, in our opinion, approaches taken to optimize outcomes in HCT for MF could be applied to those with MPN, NOS/MPN-U given a lack of contemporary data to guide best practice.³ The recommendations for MPN, NOS/MPN-U are included in [Table 7](#).

MDS/MPN with neutrophilia (WHO)/atypical CML (ICC)

Life expectancy of patients with MDS/MPN with neutrophilia/aCML is, in general, short, with a sizable proportion (up to 40%) transforming into AML within 12 to 18 months from diagnosis and a median OS reported in the 12- to 24-month range.^{51,52} Despite the advent of novel targeted therapies and drug combinations currently under active investigation, HCT remains the only curative option. Factors reported as associated with inferior survival by retrospective analyses of a limited-size patient series include age >65 years, presence of cytopenias (anemia and thrombocytopenia), leukocytosis, elevated lactate dehydrogenase level, higher marrow blast percentage, and/or presence of pathogenetic *TET2* mutations, with several models proposed to stratify patients at diagnosis according to the risk of disease-associated death.⁵²⁻⁵⁵ However, median survival remained extremely poor, even in the lower-risk groups (<2 years' median OS).

An EBMT registry-based retrospective study of 42 patients reported that half of patients were alive after 6 years after transplant.¹⁴ A smaller Japanese experience with shorter follow-up demonstrated comparable results.¹⁵ The MD Anderson group reported on 65 patients, 7 of whom underwent transplant. Median survival for the nontransplant cohort was 24.6 months and not reached in the transplant cohort.⁵² There are no robust data on whether pretransplant treatment influences outcomes after transplantation. Leukocytosis is typically

managed with cytoreductive agents, like hydroxyurea or immunomodulation with interferon. Hypomethylating agents (HMAs) and/or chemotherapy-based induction regimens are usually favored when there is a high blast count in advanced stages of the disease, particularly in the context of AML transformation. [Table 8](#) lists the panel's recommendations for this entity.

MDS/MPN with SF3B1 mutation and thrombocytosis (WHO)/MDS/MPN with thrombocytosis and SF3B1 mutation (ICC)

This entity, affecting often elderly individuals, generally presents a good prognosis, with a low risk of leukemic transformation and a median survival exceeding 5 years.⁵⁶ The presence of abnormal karyotype, *ASXL1/SETBP1* mutations, and/or moderate to severe anemia (hemoglobin <10 g/dL) at diagnosis or at follow-up were reported to be associated with worse prognosis, with expected median OS shorter than 1 year.⁵⁷ No well molecularly annotated cohorts of transplanted MDS/MPN with *SF3B1* mutation have been reported to date, with only a few case series or reports available.⁵⁸⁻⁶¹

MDS/MPN with ring sideroblasts and thrombocytosis, NOS (ICC only)

The absence of the canonical *SF3B1* mutation characterizes 10% to 30% of MDS/MPN with ring sideroblasts and thrombocytosis cases.⁶² However, discordant prognostic significance has been documented according to *SF3B1*-mutational status, with some recent reports showing no impact on OS and progression-free survival.⁵⁷ In analogy to patients with *SF3B1* mutation, no specific data are available in the literature regarding the role of transplantation. As shown in [Table 1](#), only 10 patients with MDS/MPN with thrombocytosis with or without *SF3B1* mutation have been reported in the EBMT registry as having undergone a transplant for this indication. Standard recommendations for HCT in MDS should hence be applied.⁶³

[Table 9](#) summarizes the recommendations for both MDS/MPN with *SF3B1* mutation and thrombocytosis (WHO)/MDS/MPN with thrombocytosis and *SF3B1* mutation (ICC) and MDS/MPN with ring sideroblasts and thrombocytosis, NOS (ICC only).

Table 8. Panel recommendations for MDS/MPN with neutrophilia (WHO)/atypical CML (ICC)

Disease	Panel recommendations
MDS/MPN with neutrophilia (WHO)/aCML (ICC)	It is recommended that eligible patients are considered for transplant early after diagnosis with a prompt donor search No recommendations can be made on optimal transplant conditioning and posttransplant disease monitoring and maintenance

Table 9. Panel recommendations for MDS/MPN with *SF3B1* mutation and thrombocytosis (WHO)/MDS/MPN with thrombocytosis and *SF3B1* mutation (ICC) and MDS/MPN with ring sideroblasts and thrombocytosis, NOS (ICC only)

Disease	Panel recommendations
MDS/MPN with <i>SF3B1</i> mutation and thrombocytosis (WHO)/ MDS/MPN with thrombocytosis and <i>SF3B1</i> mutation (ICC) and MDS/MPN with ring sideroblasts and thrombocytosis, NOS (ICC only)	Transplant should be considered in high-risk eligible patients (eg, refractory anemia, adverse cytogenetics, and/or presence of <i>ASXL1</i> or <i>SETBP1</i> mutations) in both MDS/MPN with thrombocytosis with or without <i>SF3B1</i> mutation, with a prompt donor search It is recommended that standard guidelines for MDS pertaining to transplant platform are applied

MDS/MPN, NOS (WHO/ICC)

MDS/MPN, NOS remains an exceedingly rare disease entity with no established consensus on optimal therapy and a dismal prognosis. A 2-center report on 135 patients highlighted a median leukemia-free survival of 24 months.²¹ Evaluation of a cohort of 85 patients from the MD Anderson center, followed up from 1987 to 2013, reported a worse life expectancy, approaching 1 year.⁶⁴ Additionally, the presence of *TP53* mutations confers higher risk of progression.⁶⁵ Regarding treatment approaches, in the above-mentioned experience, 59 of 135 received HMAs but overall had poor responses (only 1 patient achieving a complete remission [CR]). Eight (6%) patients underwent HCT, of whom 5 (63%) were alive and disease free at the last follow-up.²¹ The largest transplant series to date comes from the Japanese Society for Hematopoietic Cell Transplantation,¹⁶ which included a cohort of 86 MDS/MPN, NOS patients who underwent transplant between 2001 and 2017 using a heterogeneous range of transplant platforms. Disease status (stable/responsive vs progressive) and advanced age were significant prognostic factors for transplant outcomes, with overall long-term survival approaching 50%. Recently, the North American cooperative group reported on a cohort of 120 patients with MDS/MPN, including 48 NOS/U cases, who underwent haploidentical transplantation, primarily with RIC and nonmyeloablative conditioning regimens. Interestingly, transplant outcomes were comparable to those observed in CMML and other MDS/MPN overlap syndromes, with younger age (<65 years) and absence of splenomegaly identified as independent favorable factors for survival after transplant.⁶⁶ All these data support the potential application of CMML-like transplant strategies even in the context of MDS/MPN, NOS.⁶ Cytoreductive agents, like hydroxyurea or immunomodulation with interferon, are typically used to manage increased leukocyte proliferation, whereas HMAs may be considered for patients with predominant cytopenias and/or increased blast count. JAK inhibitors, alone or combined with HMAs, have also been investigated.⁶⁷ For younger patients progressing to AML, induction treatment is used as a bridge to HCT. Table 10 provides the panel's recommendations for this entity.

Chimerism and MRD assessment

The panel agreed that chimerism and MRD monitoring should be performed in the post-HCT period, where relevant. This will facilitate data collection in an area where there is a major lack of robust evidence. A range of techniques to assess lineage-specific chimerism are available, most commonly assessed via the polymerase chain reaction (PCR) analysis of short tandem repeats to define host and donor populations.⁶⁸ The role of CD34⁺ specific chimerism requires evaluation. MRD assessment for these disease entities remains experimental, but if assessed, sensitive laboratory techniques are preferred, ideally with a sensitivity of 0.01% to 1%, and consideration to use of digital PCR or quantitative PCR. These recommendations are as per recently suggested by the EBMT group for MRD assessment in MF as no specific guidelines exist for the specific diseases covered in these guidelines.⁶⁹ The panel agreed that use of extended NGS panels for MRD assessment remains a research tool at present. Timing of assessment is as per individual institutional policies.

Unanswered questions and future research areas

Several critical questions remain unanswered in the field of nonclassical MPN and MDS/MPN. First, a better understanding of disease prognostication is essential, and ongoing efforts, such as the International Working Group registry, are expected to provide valuable insights. Additionally, pretransplant treatment strategies across the range of disorders need to be optimized to improve outcomes, as current protocols vary significantly between institutions. A relevant issue will be the determination of transplant eligibility, which remains poorly defined. Given the older age of many patients, frailty screening to assess physical function and capacity is an area of paramount importance. This screening could also incorporate tools to more specifically evaluate cognitive function, comorbidities, social status, anxiety, and nutrition, ensuring a thorough assessment of the patient's overall health and eligibility for transplantation.⁷⁰ In this regard, a strict age limit should not be

Table 10. Panel recommendations for MDS/MPN, NOS

Disease	Panel recommendations
MDS/MPN, NOS	It is recommended that eligible patients are considered for transplant early after diagnosis, with a prompt donor search It is recommended that standard guidelines for CMML pertaining to transplant platform are applied

imposed. Instead, it seems reasonable to extend transplant evaluation up to 70 years and, in selected fit patients, even up to 75 years.

Furthermore, donor matching is a crucial factor in weighing the risks and benefits of transplantation, although this aspect has not been extensively addressed in this particular setting. All these considerations are fundamental when discussing transplant indications and must be carefully balanced against the intrinsic risk of the disease, which remains largely undefined in many scenarios. Given the available evidence, it is not possible to recommend a one-size-fits-all timing for every case and transplant center. However, it seems reasonable to initiate the search for a donor (preferably a related donor, or an unrelated/alternative donor when necessary) early in all patients affected by diseases with an expected survival of <5 years, taking into account comorbidities, transplant risks, and patient preferences.

Another important aspect is identifying the optimal transplantation platform, including the choice of donor, the intensity of the conditioning regimen, and the approach to graft-versus-host disease prophylaxis, to achieve superior long-term outcomes across various patient populations. Disease monitoring, especially in cases where molecular markers are available, requires standardization to ensure consistent and reliable assessments across different centers. Furthermore, the role of donor lymphocyte infusion and maintenance therapy, particularly when TKIs are available, remains an area of active investigation. Finally, there is an urgent need for international prospective trials with harmonized protocols to establish universally accepted treatment guidelines and improve patient outcomes across diverse health care settings. In this context, this document will be useful in guiding future research activities, providing a framework for addressing these critical unanswered questions, and driving advancements in the field.

Acknowledgment

The authors sincerely thank Linda Koster, study coordinator of the European Society for Blood and Marrow Transplantation (EBMT), for her contribution in providing transplant procedure data from the EBMT registry.

Authorship

Contribution: N. Polverelli and D.P.M. proposed the topic for practice recommendations and led the literature review; C.G., K.R., J.C.H.-B., F.O., N. Polverelli, and D.P.M. identified key clinical questions and areas of unmet clinical needs to guide consensus development; C.G. and K.R. organized the task force for the "Current State of the Art"

section; J.C.H.-B. and D.P.M. focused on nonclassical MPNs; N. Polverelli and F.O. addressed nonclassical MDS/MPNs; D.A.A., N.C.P.C., P.G., C.H., J.D.K., J.J.K., L.M., R.M., E.P., F. Palandri, M.M.P., A.O., D.H.R., A.R., and D.H.W. drafted "Current State of the Art"; G.B., F.C., T.C., V.F., N. Gagelmann, N. Gangat, J.G., T.J., F. Passamonti, N. Pemmaraju, and I.Y.-A. contributed to "Nonclassical MPN"; L.A., F.B.D., Y.C., J.D.-S., G.H., N.K., M.M., M.R., D.R., C.S., K.S., A.T., and A.M.V. worked on "Nonclassical MDS/MPN"; the preliminary draft was thoroughly reviewed by N. Polverelli, K.R., M.K., M.R., J.D.-S., T.C., J.C.H.-B., F.O., I.S.-O., I.Y.-A., and D.P.M., who prepared the final draft; and all authors reviewed the manuscript and approved its final version.

Conflict-of-interest disclosure: J.G. was included in the response adjudication committee for FIGHT-203 trial (Pemigatinib in FGFR1-Rearranged MLN). N. Gangat received fees for advisory board for DISC Medicine and Agios. Y.C. has received institutional consulting fees for advisory board from Merck Sharp & Dohme (MSD), Novartis, Incyte, Bristol Myers Squibb (BMS), Pfizer, AbbVie, Roche, Jazz, Gilead, Amgen, AstraZeneca, Servier, Takeda, Pierre Fabre, and Medac and has received travel support from MSD, Roche, Novartis, Pfizer, BMS, Gilead, Amgen, Incyte, AbbVie, Janssen, AstraZeneca, Jazz, Pierre Fabre, and Sanofi, all via the institution. T.J. received institutional research support from CTI Biopharma, Kartos Therapeutics, Incyte, BMS, Tscan, Karyopharm Therapeutics; serves on the advisory board of BMS, Incyte, AbbVie, CTI, Kite, Cogent Biosciences, Blueprint Medicine, Telios Pharma, Protagonist Therapeutics, Galapagos, Tscan Therapeutics, Karyopharm, Morphosys, and In8Bio. The remaining authors declare no competing financial interests.

ORCID profiles: N. Polverelli, 0000-0001-6297-9697; J.C.H.-B., 0000-0002-4289-3113; C.G., 0000-0001-6829-5544; K.R., 0000-0002-8258-354X; T.C., 0000-0003-3108-4035; M.K., 0000-0002-1859-6178; M.R., 0000-0003-1388-9876; I.S.-O., 0009-0005-5519-9154; D.A.A., 0000-0002-2160-9689; G.B., 0000-0002-5201-1786; Y.C., 0000-0001-9341-8104; N.C.P.C., 0000-0001-5481-2555; J.D.-S., 0000-0002-4562-6264; V.F., 0000-0002-2122-7277; N. Gangat, 0000-0002-9104-6172; G.H., 0000-0002-0199-9333; T.J., 0000-0001-6854-773X; J.D.K., 0000-0003-2621-3584; J.J.K., 0000-0002-8121-438X; N.K., 0000-0001-5103-9966; L.M., 0000-0002-1460-1611; M.M., 0000-0002-3987-419X; R.M., 0000-0001-5880-7972; F. Palandri, 0000-0001-8367-5668; M.M.P., 0000-0001-6998-662X; N. Pemmaraju, 0000-0002-1670-6513; C.S., 0009-0007-6539-226X; D.H.W., 0000-0003-0715-1402; I.Y.-A., 0000-0003-4524-8782.

Correspondence: Nicola Polverelli, Unit of Bone Marrow Transplantation and Cellular Therapies, Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, 27100 Pavia, Italy; email: n.polverelli@smatteo.pv.it.

Footnotes

Submitted 9 December 2024; accepted 23 February 2025; prepublished online on *Blood* First Edition 19 March 2025. <https://doi.org/10.1182/blood.2024028000>.

The online version of this article contains a data supplement.

REFERENCES

- Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200-1228.
- Khoury JD, Solary E, Ablat O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *Leukemia*. 2022;36(7):1703-1719.
- Kröger N, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. *Lancet Haematol*. 2024;11(1):e62-e74.
- Polverelli N, Hernandez-Boluda JC, Gagelmann N, et al. Navigating "grey areas" and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT. *Bone Marrow Transpl*. 2024;60(1):10-18.
- Hernández-Boluda JC, Eikema DJ, Koster L, et al. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. *Bone Marrow Transpl*. 2023;58(12):1357-1367.
- Onida F, Gagelmann N, Chalandon Y, et al. Management of adult patients with CMML undergoing allo-HCT: recommendations

- from the EBMT PH&G Committee. *Blood*. 2024;143(22):2227-2244.
7. Yakoub-Agha I, Greco R, Onida F, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. *Bone Marrow Transpl*. 2023;58(6):696-700.
 8. Dholaria B, Radujkovic A, Estrada-Merly N, et al. Outcomes of allogeneic hematopoietic cell transplantation for chronic neutrophilic leukaemia: a combined CIBMTR/CMWP of EBMT analysis. *Br J Haematol*. 2022;198(4):785-789.
 9. McLoman DP, Gras L, Martin I, et al. Outcome of allogeneic hematopoietic cell transplantation in eosinophilic disorders: a retrospective study by the chronic malignancies working party of the EBMT. *Br J Haematol*. 2022;198(1):209-213.
 10. McLoman DP, Malpassuti V, Lippinkhof-Kozijn A, et al. Outcome of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT. *Br J Haematol*. 2020;190(3):437-441.
 11. Metzgeroth G, Steiner L, Naumann N, et al. Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort. *Leukemia*. 2023;37(9):1860-1867.
 12. Hernández-Boluda JC, Pereira A, Zinger N, et al. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. *Bone Marrow Transpl*. 2022;57(3):416-422.
 13. Tang G, Tam W, Short NJ, et al. Myeloid/lymphoid neoplasms with FLT3 rearrangement. *Mod Pathol*. 2021;34(9):1673-1685.
 14. Onida F, de Wreede LC, van Biezen A, et al. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. *Br J Haematol*. 2017;177(5):759-765.
 15. Itonaga H, Ota S, Ikeda T, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan. *Leuk Res*. 2018;75:50-57.
 16. Kurosawa S, Shimomura Y, Tachibana T, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable: a retrospective nationwide study of the Japan Society for Hematopoietic Cell Transplantation. *Biol Blood Marrow Transpl*. 2020;26(9):1607-1611.
 17. Meggendorfer M, Jeromin S, Haferlach C, Kern W, Haferlach T. The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms. *Haematologica*. 2018;103(5):e192-e195.
 18. Palomo L, Meggendorfer M, Hutter S, et al. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. *Blood*. 2020;136(16):1851-1862.
 19. Gambacorti-Passerini CB, Donadoni C, Parmiani A, et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. *Blood*. 2015;125(3):499-503.
 20. Lasho TL, Finke CM, Zblewski D, et al. Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. *Blood Cancer J*. 2015;5:e275.
 21. Mangaonkar AA, Swoboda DM, Coltro G, et al. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. *Leukemia*. 2020;34(2):656-661.
 22. Padron E. Toward classifying the unclassifiable. *Blood*. 2020;136(16):1800-1801.
 23. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20):2391-2405.
 24. Szuber N, Elliott M, Tefferi A. Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management. *Am J Hematol*. 2022;97(4):491-505.
 25. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. *N Engl J Med*. 2013;368(19):1781-1790.
 26. Gangat N, Guglielmelli P, Szuber N, et al. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases. *Am J Hematol*. 2021;96(7):781-789.
 27. Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. *Leukemia*. 2005;19(2):313-317.
 28. Carreño-Tarragona G, Álvarez-Larrán A, Harrison C, et al. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes. *Blood Adv*. 2023;7(9):1672-1681.
 29. Lee SE, Jo I, Jang W, Kim Y, Han K, Kim M. T618I-mutated colony stimulating factor 3 receptor in chronic neutrophilic leukemia and chronic myelomonocytic leukemia patients who underwent allogeneic stem cell transplantation. *Ann Lab Med*. 2015;35(3):376-378.
 30. Morsia E, Reichard K, Pardanani A, Tefferi A, Gangat N. WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): a contemporary series from the Mayo Clinic. *Am J Hematol*. 2020;95(7):E172-E174.
 31. Helbig G, Soja A, Bartkowska-Chrobok A, Kyrz-Krzemień S. Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. *Am J Hematol*. 2012;87(6):643-645.
 32. Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. *Blood*. 2017;129(6):704-714.
 33. Reiter A, Metzgeroth G, Cross NCP. How I (diagnose and) treat myeloid / lymphoid neoplasms with tyrosine kinase gene fusions. *Blood*. 2025;145(16):1758-1768.
 34. Shomali W, Colucci P, George TI, et al. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group. *Leukemia*. 2023;37(5):981-987.
 35. Rohmer J, Couteau-Chardon A, Trichereau J, et al. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRα-positive myeloid neoplasm with eosinophilia: data from 151 patients. *Am J Hematol*. 2020;95(11):1314-1323.
 36. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. *Blood*. 2014;123(23):3574-3577.
 37. Metzgeroth G, Schwaab J, Gosenca D, et al. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. *Leukemia*. 2013;27(11):2254-2256.
 38. Metzgeroth G, Schwaab J, Naumann N, et al. Treatment-free remission in FIP1L1-PDGFRα-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. *Blood Adv*. 2020;4(3):440-443.
 39. Metzgeroth G, Erben P, Martin H, et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRα positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. *Leukemia*. 2012;26(1):162-164.
 40. Zhang Y, Gao Y, Zhang H, et al. PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. *Blood*. 2018;131(20):2256-2261.
 41. Lierman E, Smits S, Cools J, Dewaele B, Debiec-Rychter M, Vandenberghe P. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRα and KIT, and against FGFR1-derived fusion kinases. *Leukemia*. 2012;26(7):1693-1695.
 42. Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRα D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label,

- phase 1 trial. *Lancet Oncol*. 2020;21(7):935-946.
43. Schwaab J, Naumann N, Luebke J, et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. *Am J Hematol*. 2020;95(7):824-833.
 44. Verstovsek S, Subbiah V, Masarova L, et al. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. *Ann Oncol*. 2018;29(8):1880-1882.
 45. Iurlo A, Gianelli U, Cattaneo D, Thiele J, Orazi A. Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: comparison with the 2008 version. *Am J Hematol*. 2017;92(4):E48-E51.
 46. Deschamps P, Moonim M, Radia D, et al. Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre. *Br J Haematol*. 2021;193(4):792-797.
 47. McLornan DP, Hargreaves R, Hernández-Boluda JC, Harrison CN. How I manage myeloproliferative neoplasm-unclassifiable: practical approaches for 2022 and beyond. *Br J Haematol*. 2022;197(4):407-416.
 48. Crane GM, Geyer JT, Thakral B, et al. Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study. *Am J Clin Pathol*. 2024;162(3):233-242.
 49. Hargreaves R, Harrison CN, McLornan DP. Diagnostic and management strategies for myeloproliferative neoplasm-unclassifiable (MPN-U): an international survey of contemporary practice. *Curr Res Transl Med*. 2022;70(3):103338.
 50. Polverelli N, Hernández-Boluda JC, Czerw T, et al. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. *Lancet Haematol*. 2023;10(1):e59-e70.
 51. Szuber N, Orazi A, Tefferi A. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. *Am J Hematol*. 2024;99(7):1360-1387.
 52. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, et al. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. *Cancer*. 2021;127(17):3113-3124.
 53. Onida F, Ball G, Kantarjian HM, et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. *Cancer*. 2002;95(8):1673-1684.
 54. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. *Am J Hematol*. 2017;92(6):542-548.
 55. Gotlib J. How I treat atypical chronic myeloid leukemia. *Blood*. 2017;129(7):838-845.
 56. Li F, Qin T, Li B, et al. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis. *Leukemia*. 2024;38(6):1334-1341.
 57. Patnaik MM, Lasho TL, Finke CM, et al. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. *Am J Hematol*. 2016;91(5):492-498.
 58. Sharma P, Shinde SS, Damraj M, et al. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. *Leuk Lymphoma*. 2017;58(4):872-881.
 59. Mangaonkar AA, Lasho TL, Ketterling RP, et al. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. *Blood Cancer J*. 2022;12(2):26.
 60. Courville EL, Griffith M, Ustun C, Yohe S, Warlick E. Impending relapse of myelodysplastic syndrome after allogeneic transplant is difficult to diagnose and requires a multi-modal approach. *BMC Clin Pathol*. 2017;17:28.
 61. Basquiera AL, Rivas MM, Remaggi G, et al. Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: experience of the Argentinean Group of Bone Marrow Transplantation (GATMO). *Hematology*. 2016;21(3):162-169.
 62. Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 update on diagnosis, risk-stratification, and management." *Am J Hematol*. 2019;94(4):475-488.
 63. DeFilipp Z, Ciurea SO, Cutler C, et al. Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. *Transpl Cell Ther*. 2023;29(2):71-81.
 64. DiNardo CD, Daver N, Jain N, et al. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. *Leukemia*. 2014;28(4):958-961.
 65. Patnaik MM, Tefferi A. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. *Am J Hematol*. 2023;98(4):681-689.
 66. Jain T, Tsai HL, Elmariah H, et al. Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration. *Haematologica*. 2023;108(12):3321-3332.
 67. Assi R, Kantarjian HM, Garcia-Manero G, et al. A phase II trial of ruxitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. *Am J Hematol*. 2018;93(2):277-285.
 68. Kristt D, Stein J, Yaniv I, Klein T. Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility. *Bone Marrow Transpl*. 2007;39(5):255-268.
 69. McLornan DP, Hernandez-Boluda JC, Czerw T, et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. *Leukemia*. 2021;35(9):2445-2459.
 70. Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. *Hematol Am Soc Hematol Educ Program*. 2021;2021(1):254-263.

© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.